Characteristics | Univariate Analysis | Multivariate Analysis | |||
---|---|---|---|---|---|
Hazard Ratio (95% CI) | P-value | Hazard Ratio (95% CI) | P-value | ||
Gender | Male | 1 | – | – | |
Female | 1.081 (0.874–1.336) | 0.473 | – | – | |
Age in years | 10–14 | 1 | – | – | |
15–19 | 1.167 (0.939–1.450) | 0.163 | – | – | |
Geographical setting | Urban | 1 | 1 | ||
Rural | 1.703 (1.268–2.286) | 0.0001 | 6.521 (3.776–11.261) | 0.0001 | |
Level of Education | Primary | 1 | – | – | |
Secondary | 1.039 (0.810–1.332) | 0.765 | – | – | |
Tertiary | 1.190 (0.483–2.933) | 0.705 | – | – | |
None | 1.121 (0.411–3.058) | 0.823 | – | – | |
Disclosure of HIV to study participants | Yes | 1 | – | – | |
No | 1.280 (1.007–1.627) | 0.044 | – | – | |
Parental Status | Orphan | 1.200 (0.963–1.495) | 0.105 | – | – |
Non orphan | 1 | – | – | ||
Baseline CD4 count | ≥ 500 cell/mm3 | 1 | – | – | |
< 500 cell/mm3 | 1.695 (1.230–2.337) | 0.001 | |||
WHO clinical stage | Stage I/II | 1 | – | – | |
Stage III/IV | 1.039 (0.801–1.349) | 0.773 | – | – | |
Retained in care | Yes | 1 | 1 | ||
No | 1.813 (0.962–3.418) | 0.066 | 2.399 (1.156–4.979) | 0.019 | |
Anemia at start | Yes | 1 | 1 | – | |
No | 0.373 (0.204–0.684) | 0.001 | 0.207 (0.067–0.632) | 0.006 | |
Opportunistic infection | Yes | 1.333 (0.961–1.850) | 0.086 | – | – |
No | 1 | – | – | ||
Treatment Regimen | First line | 1.202 (0.815–1.771) | 0.354 | – | – |
Second line | 1 | – | – | ||
Cotrimoxazole prophylaxis | Yes | 1 | – | – | |
No | 0.820 (0.536–1.254) | 0.360 | – | – | |
Exposure to NVP prophylaxis for PMTCT | Yes | 1 | – | – | |
No | 1.845 (1.134–3.003) | 0.014 | – | – | |
Mode of Transmission | Vertical | 1 | – | – | |
Horizontal | 2.575 (1.464–4.530) | 0.001 | – | – |